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AbstrACt
Introduction Alcohol dependence is a major public health 
problem. It is underdiagnosed and undertreated. Even 
when treated, more than 2/3 of patients in abstinence-
oriented treatment will relapse within the first year. Thus, 
there is an urgent need for efficacious medical treatment 
of alcohol dependence. Glucagon-like peptide-1 (GLP-
1) receptor stimulation has proven to reduce alcohol 
consumption in preclinical experiments. However, the 
effect of GLP-1 receptor agonists in humans has to our 
knowledge, not yet been investigated.
Methods and analysis Design, participants and 
intervention: The effect of the once-weekly GLP-1-
receptor-agonist exenatide will be investigated in a 
double-blinded, placebo-controlled, randomised clinical 
trial. 114 outpatients will be recruited and randomised to 
treatment with either placebo or exenatide once weekly 
for 26 weeks as a supplement to cognitive–behavioural 
therapy. The primary endpoint is reduction in number of 
‘heavy drinking days’. The secondary endpoints include 
changes in total alcohol consumption, days without 
consumption, changes in brain activity and function, 
smoking status, cognition, measures of quality of life 
and changes in phosphatidylethanol as a biomarker of 
alcohol consumption from baseline to follow-up at week 
26. Status: Currently recruiting patients.
Ethics and dissemination Ethical approval has been 
obtained. Before screening, all patients will be provided oral 
and written information about the trial. The study results will 
be disseminated by peer-review publications and conference 
presentations and has the potential to reveal a completely 
new medical treatment of alcohol dependence.
IntroduCtIon
Alcohol dependence is a major global public 
health problem across the world.1 2 It is an 
underdiagnosed and undertreated3 condition 
and more than 2/3 of patients in abstinence-ori-
ented treatment will relapse within the first 
year.4 In Denmark, approximately 20% of the 
population is consuming more alcohol than 
recommended by the Danish National Board 
of Health.5 Further, 8.5% of the Danish adult 
population (16 years or older) has a ‘risky’, that 
is, potentially harmful, alcohol consumption, 
defined as more than 14 and 21 units of alcohol 
(one unit defined as 12 g of pure alcohol) 
for women and men per week, respectively.6 
Three per cent fulfil the criteria for alcohol 
dependence.7 
strengths and limitations of this study
 ► The trial is a double-blinded, randomised, place-
bo-controlled trial which is designed, to evaluate the 
effects of the glucagon-like peptide-1 receptor ag-
onist exenatide on alcohol consumption in patients 
with alcohol dependence.
 ► The study duration is 26 weeks which is longer than 
most previous studies investigating medical treat-
ment of alcohol dependence.
 ► The biological basis for any demonstrated effect is 
investigated with brain imaging techniques and the 
biomarker phosphatidylethanol.
 ► A possible limitation is that the alcohol intake is 
self-reported which potentially could affect accuracy.
 ► Another limitation is that the study has no third 
treatment arm for comparing exenatide to one of the 
known compounds used in the clinic against alcohol 
use disorder, for example, disulfiram, acamprosate 
or naltrexone.
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Psychological treatment
One of the best documented treatments of alcohol 
dependence is cognitive–behavioural therapy (CBT).8 
The underlying neuroanatomical basis of alcohol addic-
tion and treatment effects of CBT are not yet established, 
although functional MRI (fMRI) studies have begun to 
elucidate the neural underpinnings of alcohol depen-
dence.9 Alcohol-dependent patients have been found to 
display increased dorsal anterior cingulate cortex acti-
vation during spatial working memory (SWM), perhaps 
reflecting decreased prefrontal efficiency because of 
distracting alcohol-related thoughts.10 Interestingly, it 
was also recently demonstrated that alcohol-dependent 
patients also display increased neural activation to alcohol 
associated cues in mesocorticolimbic networks; which is 
normalised with psychological therapy.9
Pharmacological treatment
Pharmacological treatment of alcohol dependence is 
considered an important supplement to psychological 
therapy.11 Disulfiram, a substance that blocks alcohol-me-
tabolising enzymes resulting in increased acetaldehyde 
concentrations, was introduced in Denmark in 1948.12 
Newer pharmacological agents, such as acamprosate, a 
gamma-aminobutyric acid receptor agonist and a N-Meth-
yl-D-aspartate receptor antagonist; and naltrexone, a mu 
and kappa opioid receptor antagonist are now used as 
alternate treatments for alcohol dependence. However, 
these compounds have not gained widespread dissemi-
nation, probably because the effect of the substances is 
modest, with a less than 10% increase in abstinent rate 
compared with placebo.13 The antiepileptic compound 
topiramate has shown promising results in clinical trials14 
and another pharmacological agent, nalmefene, with a 
mechanism of action somewhat similar to naltrexone, has 
very recently been approved by the European Medicines 
Agency as a medication for reducing alcohol consump-
tion.15 Clearly, given the moderate success rates of CBT8 
and the synergistic effects of adding pharmacological 
treatment — as described in this section — are quite 
limited, there is an urgent need for new and more effi-
cient treatment modalities of alcohol dependence.
Glucagon-like peptide-1 and GLP-1 receptor agonists
Glucagon-like peptide-1 (GLP-1)-based therapy for the 
treatment of type 2 diabetes was introduced in 2006.16 
GLP-1 is an incretin hormone, which is secreted from 
endocrine L cells of the small intestine in response to 
nutrients in the gut lumen.17 GLP-1 conveys an insuli-
notropic effect through GLP-1 receptors (GLP-1R) on 
the beta cells of the pancreas and inhibits the secretion 
of glucagon from the alpha cells of the pancreas, which 
lower the blood glucose level.18 Naturally occurring 
GLP-1 is rapidly degraded within minutes by the enzyme, 
dipeptidyl peptidase-4.17 Exendin-4, originally isolated 
from the saliva of a lizard species, the Gila monster, has 
53% sequence homology with human GLP-1 in its first 30 
amino acids. Exenatide binds to the GLP-1R with high 
affinity19 and acts as a receptor agonist, thus referred to 
as a GLP-1 receptor agonists (GLP-1RA).
GLP-1rA: a potential new treatment for alcohol use disorder?
GLP-1RA has a well-established effect on the food reward 
system which seems to be driven by two key mesolimbic 
brain regions, the ventral tegmental area (VTA) and 
nucleus accumbens (NAc).20 These regions are involved 
in the rewarding properties of food and to drugs of abuse, 
including alcohol.21–23 Interestingly, GLP-1 receptors 
(GLP-1R) are expressed in these brain reward regions 
(VTA and NAc), which are innervated by hindbrain GLP-1 
neurons.21 A link between alcohol intake and GLP-1 has 
been demonstrated in studies and is considered to play 
a central role in the development of addiction to stim-
ulant drugs (ie, cocaine, amphetamine, alcohol).24 The 
findings are consistent with the hypothesis, that systemic 
administration of GLP-1RA can influence the mesolimbic 
dopamine system and reward-seeking behaviours associ-
ated with alcohol dependence.25 Although the precise 
mechanism of action has not been elucidated in vivo, 
we recently reported that in vitro, exendin-4 induces 
an upregulation of the dopamine transporter (DAT) 
function.26
Given this collective evidence, we aim to investigate 
whether the beneficial effect of the GLP-1RA, exenatide, 
on alcohol consumption in preclinical studies, can be 
translated to patients with known alcohol use disorder.27
Hypothesis
 ► Exenatide treatment will decrease alcohol consump-
tion, measured as total number of heavy drinking 
days, in alcohol-dependent patients.
 ► Exenatide will induce upregulation of the striatal DAT 
availability, in alcohol-dependent patients.
 ► Exenatide will modulate neural responses in reward 
processing regions including NAc.
To test these hypothesis, we have designed a 26-week, 
clinical trial including 114 patients with known alcohol 
dependence. To explore the underlying neuromo-
lecular mechanism(s) of the potential positive effect of 
exenatide versus placebo on alcohol consumption, we 
will obtain single-photon emission CT (SPECT) neuro-
imaging of DAT at weeks 0 and 26 in a subgroup of the 
patients. Further, the functional brain network modu-
lated by the possible treatment effects will be investigated 
in a subgroup using fMRI at weeks 0 and 26.
MEtHods And AnALysIs
study design
The present study is a 26-week, double-blinded, 
randomised, placebo-controlled clinical trial, designed 
to evaluate the effects of exenatide versus placebo in 114 
patients, diagnosed with alcohol dependence according to 
the International Classification of Diseases, 10th Edition 
(ICD-10) and with an alcohol use disorder according 
to the The Diagnostic and Statistical Manual of Mental 
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Disorders, Fifth Edition (DSM-5) criteria. The patients 
will be recruited from the Novavì outpatient clinics in 
Copenhagen, Denmark. To be eligible for participation, 
the patients will first undergo screening according to 
the inclusion and exclusion criteria. When consented 
and included, the patient will meet to get his/her weekly 
injection by the unblinded nurse. The nurse will collect 
a weekly alcohol diary and hand out a new one, for the 
following week.
Participants and screening
The patients will be recruited from outpatient units, 
specifically, the Novavì outpatient clinics in suburbs of 
Copenhagen, Denmark. All patients will receive psycho-
social alcohol treatment based on psycho educative 
elements, motivational interviewing and CBT. Skilled 
staff members will be administering the psychosocial 
treatment in the clinic. The recruitment procedure starts 
as a prescreening when the patients contact the Novavì 
outpatient clinics, which are open outpatient clinics. All 
potentially eligible patients will be fully informed, verbally 
as well as in writing, of their rights and responsibilities 
while participating in the trial. Screening examinations 
will only be performed after the patient has agreed to 
participate and has signed the informed consent form.
At the time of screening, the patients will undergo a series 
of examinations to assure that all inclusion and none of the 
exclusion criteria are met. The patients will be asked general 
information about psychosocial factors, that is, education 
level, employment status and marital status. In addition, 
somatic symptoms and baseline medications will be regis-
tered. Blood samples and a urine tests will be collected for 
acute analysis according to the exclusion criteria. Further-
more, blood samples and urine samples will be saved for an 
investigational biobank that will allow more advanced anal-
yses, for example, phosphatidylethanol (PEth). The most 
important tests and examinations are described in details in 
later sections. See also figure 1 for a complete schedule of 
events. The inclusion frequency will be regularly evaluated, 
and we have the option of including more trial centres to 
assure recruitment.
Intervention
The pharmacological intervention will be given as an 
add-on to the standardised psychosocial alcohol treat-
ment paradigm. Exenatide is delivered from Region 
Hovedstadens Apotek as a powder with solvent for 
prolonged release injection (once weekly). Each single-
dose, dual-chamber pen contains 0.65 mL of diluent 
and 2 mg of exenatide, which are isolated until mixed 
by the nurse administering the drug. The placebo will 
be supplied as prefilled saline syringes (0.9% saline), 
by Region Hovedstadens Apotek and will be adminis-
tered in the same way and volume as exenatide. The 
unblinded nurse, with no involvement in the psycho-
social treatment, will administer the drug injections, 
and the patients will be blindfolded while receiving 
the once-weekly injections. To promote participant 
retention, the nurse will contact the patient if he or she 
does not show up for the weekly injection.
Inclusion criteria
 ► Informed oral and written consent.
 ► Diagnosed with alcohol dependence according to the 
criteria of ICD-10, WHO and DSM-5 (for the equiva-
lent diagnosis of alcohol use disorder).
 ► Alcohol Use Disorder Identification Test (AUDIT) 
score >15.28
 ► Age 18–70 years (both included).
 ► Heavy alcohol drinking defined as having alcohol 
consumption over 60 g of alcohol per day (men) or 
48 g of alcohol per day (women) for at least 5 days in 
the past 30 days prior to inclusion measured by the 
Timeline Followback Method (TLFB) method.
Exclusion criteria
 ► Severe psychiatric disease, for example, a diagnosis of 
schizophrenia, paranoid psychosis, bipolar disorder 
or mental retardation.
 ► A history of delirium tremens or alcohol withdrawal 
seizures.
 ► No serious withdrawal symptoms at inclusion (defined 
as a score higher than 9 on Clinical Institute With-
drawal Assessment for Alcohol Scale, Revised at base-
line examinations).
 ► Current or history of neurological disease including 
traumatic brain injury.
 ► Current or history of diagnosis of type 1 or type 2 
diabetes or plasma haemoglobin A1c (HbA1c) ≥48 
mmol/mol equivalent to 6.5% at inclusion.
 ► Women of childbearing potential who are pregnant, 
breast feeding or have intention of becoming preg-
nant within the next 9 months, or are not using contra-
ceptives (during the whole study period) considered 
as highly effective.29
 ► Impaired hepatic function (liver transami-
nases >3 times upper normal limit).
 ► Impaired renal function (estimated glomerular filtra-
tion rate (eGFR)) <50 mL/min).
 ► Impaired pancreatic function (any history of acute or 
chronic pancreatitis and/or amylase >2 times upper 
limit).
 ► S-triglycerides >10 mmol/L.
 ► History of medullary thyroid carcinoma (MTC) and/
or family history with MTC and/or multiple endo-
crine neoplasia syndrome type 2.30
 ► Cardiac problems defined as decompensated heart 
failure (New York Heart Association functional class 
III or IV), unstable angina pectoris and/or myocar-
dial infarction within the last 12 months.
 ► Uncontrolled hypertension (systolic blood pressure 
>180 mm Hg, diastolic blood pressure >110 mm Hg).
 ► Concomitant pharmacotherapy against alcohol 
dependence, that is, disulfiram, naltrexone, acam-
prosate and nalmefene or treatment with any of these 
compounds within 1 month prior to inclusion.
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 ► Concomitant pharmacotherapy with dopamine active 
drugs, such as some types of attention deficit hyperac-
tivity disorder medication (methylphenidate).
 ► Receiving any investigational drug within the last 
3 months.
 ► Use of weight-lowering pharmacotherapy within the 
preceding 3 months.
 ► Any other active substance use defined as a Drug Use 
Disorders Identification Test (DUDIT)-score31 >6 (for 
men) >2 (for women) and fulfilling the criteria’s for 
dependence of the substance according to the criteria 
of ICD-10 (except nicotine).
 ► Body mass index <18.5 kg/m2.
 ► Only for patients undergoing brain scans:
 – Contraindications for MR scanning (magnetic im-
plants, pacemaker, claustrophobia etc).
 – Contraindications for SPECT scanning (radiation 
exposure, excluding background radiation but 
including diagnostic X-rays and other medical ex-
posures exceeding 10 mSv in the last 12 months, al-
lergy towards iodine).
 ► Unable to speak and/or understand Danish.
 ► Any condition that the investigator feels would inter-
fere with trial participation.
Withdrawal criteria
Patients are free to withdraw from the trial at any time 
without providing a reason therefore and without impact 
on further treatment at the Novavì outpatient clinics. The 
reason for withdrawal may be withdrawal of consent, treat-
ment failure, adverse event, pregnancy discovered during 
the trial or profound increase in alcohol consumption. 
Figure 1 Study flow diagram. DAT, dopamine transporter; fMRI, functional MRI; SPECT, single-photon emission CT; TLFB, 
Timeline Followback.
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Failure to comply with clinical trial medication, that is, if 
the patient misses more than three consecutive injections 
or more than five injections in total leads to exclusion.
timeline Followback Method
At weeks 0, 4, 12, 20 and 26, the examiner will—in close 
collaboration with the patient—fill out the TLFB schedule 
for the last 30 days, based on the weekly collected alcohol 
diaries. The TLFB has been extensively tested and evalu-
ated32 and has, in addition, been demonstrated to have a 
high test–retest reliability in previous studies.33 The infor-
mation collected by the TLFB will be used to evaluate 
effects on the primary endpoint, that is, number of heavy 
drinking days.
blood analyses
At every examination, a variety of routine blood samples 
will be drawn. This is to monitor that the patients have 
no serious adverse reactions to the treatment compro-
mising liver, kidney or pancreatic function. HbA1c will 
only be analysed at week 0 and week 26. At week 0 and 
week 26, blood will also be drawn for two advanced tests, 
proteomics and bone markers. At every examination, 
blood will be drawn for the advanced test PEth which is 
the biomarker with the best correlation to self-reported 
alcohol consumption and it can reflect alcohol consump-
tion during several weeks prior to sampling.34 In the 
present study, we will be investigating the proteomic 
fingerprint as it is known that levels of humoral cytokines 
can be affected in alcohol-related liver diseases and that 
GLP-1RAs have an additional impact on humoral cyto-
kines.35 We will also measure plasma levels of the bone 
markers collagen type 1 C-telopeptide and procollagen 
type 1 N-terminal propeptide, as former studies show that 
another incretin hormone (GIP (Gastric Inhibitory Poly-
peptide)) reduces bone resorption.36
urine analyses
At baseline (week 0) and at the final examination (week 
26), a urine sample will be collected. This is for a routine 
screening of albumin:creatinine ratio and oxidative stress 
parameters. Oxidative stress, that is, excessive reactive 
oxygen species, can cause cell-damaging effects through 
oxidative modification of macromolecules leading to 
their inappropriate functions. Such oxidative modifica-
tion is related to cancers, ageing, and neurodegenerative 
and cardiovascular diseases.37 Studies in rats have shown 
that the GLP-1RA liraglutide may have a direct beneficial 
effect on oxidative stress and diabetic nephropathy.38
Questionnaires
To assess potential psychopathology and drug use, a 
number of questionnaires will be administered at week 
0 and at week 26 including: quality of life (Short Form 
Health Survey (SF-36)), psychopathology (Symptom 
Checklist (SCL-92)), depression symptoms (Major 
Depression Inventory (MDI)), alcohol consumption 
(AUDIT (Alcohol Use Disorders Identification Test)), 
craving (Penn Alcohol Craving Scale (PACS)), smoking 
(Fagerström Test for Nicotine Dependence) and drug 
use (DUDIT (Drug Use Disorders Identification Test)).
screen for Cognitive Impairment in Psychiatry test
The Screen for Cognitive Impairment in Psychiatry 
(SCIP) is a brief (<20 min) and feasible neuropsycholog-
ical instrument for screening for cognitive dysfunction in 
patients with psychotic and affective disorders39 and in 
healthy controls.40 It will be administered at week 0, 4 and 
26 in three parallel equivalent forms to minimise learning 
effects.
single-photon emission Ct
A subgroup of 40 patients will have a SPECT scan 
performed at baseline and after 26 weeks of treatment. 
We will use the SPECT brain scan with the DAT ligand 
123I-2-b-carbomethoxy-3b-(4-iodophenyl)-N-(3-fluoro-
propyl) nortropane ((123I)-FP-CIT (Ioflupane 123I), 
DaTSCAN) administrated as a bolus injection. The 
(123I)-FP-CIT binding potential is used to calculate an 
estimate of DAT availability in regions of interest. As no 
human data are available on the effects of GLP-1RA in 
DAT availability, we also propose to investigate DAT avail-
ability in healthy, non-alcohol-dependent subjects. The 
study on the healthy subjects is performed in order to 
investigate possible acute effects of exenatide on DAT 
availability in the human brain. Possible long-term effects 
of GLP-1R stimulation will be explored through scans at 
week 26 in the present study.
Functional MrI
The neuroanatomical underpinnings of the possible 
treatment effects will be investigated using fMRI at week 
0 and 26. We will investigate brain activity during expo-
sure to alcohol cues and during SWM performance. 
Furthermore, we will evaluate the effects of exenatide 
versus placebo on functional connectivity in the brain 
during resting state, on structural connectivity and brain 
morphology. A subgroup of 50 patients will have an 
fMRI scan performed at baseline and after 26 weeks of 
treatment. The patients will undergo two different tasks 
presented in block paradigms to maximise sensitivity 
for blood-oxygen-level dependent signal change. In the 
first task, the patients will be shown a series of alcohol-re-
lated and neutral pictures. Following each block, the 
patients rate the intensity of their alcohol craving on a 
Visual Analogue Scale.9 In the second task, the SWM will 
be assessed using an N-back version design.41 To obtain 
comparable data from healthy controls in the alcohol and 
SWM paradigms (fMRI), we will scan 25 healthy partic-
ipants. The participants will have no history of alcohol 
dependence and will be matched to the patients with 
respect to gender and age.
sample size calculation and randomisation
The primary outcome measure (total number of heavy 
drinking days) was used for the sample size calculation. 
Based on data from the study by Johnson et al,42 where 
the reduction in the percentage of total number of heavy 
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drinking days was 60.3% in the intervention group and 
32.7% in the control group, with an alpha of 5%, a power 
of 90% and with an estimated SD of 34.5, the estimated 
sample size is of 68 patients (34 in each group). With an 
estimated dropout rate of 40%, a total number of 114 
patients (57 patients in each arm) are needed.
The patients will be randomised into two groups with 
57 patients in each group using the randomisation 
module in Research Electronic Data Capture (REDCap). 
The randomisation will be stratified in terms of age (two 
levels), sex (two levels) and baseline alcohol consumption 
(ie, number of heavy drinking days measured by TLFB) 
(four levels). The block sizes will be randomised between 
2 and 4. The random allocation sequence will be gener-
ated by an extern statistician by use of the R statistical 
package blockrand and uploaded in REDCap in accor-
dance with REDCap’s user guide and reference manual.43
Patients, investigators, other care givers performing 
assessments and persons performing data analysis will 
remain blinded from the time of randomisation to time 
of database unlock. In order to maintain the blinding of 
the patients, an unblinded nurse will perform the rando-
misation and prepare the injections. If a patient develops, 
an adverse reaction that requires knowledge of the treat-
ment the randomisation will be broken for only that 
particular patient.
Patient and public involvement
No patients were involved in development of the research 
question or in designing the study, and the burden of the 
intervention is not assessed by patients themselves.
When signing the informed consent, patients are 
encouraged to fill in their email address, so they can 
receive the results of the study.
statistical analysis
Before dividing participants into two groups, the statistical 
analysis plan will be uploaded at  ClinicalTrials. gov. Anal-
yses will be made by use of R software,44 with alpha set at 
0.05 and two-sided testing. All analyses will be performed 
using the intention-to-treat principle on subjects, who 
were randomised and received at least one dose of the 
trial compound (exenatide or placebo). Missing data will 
be imputed using multiple imputations, and a sensitivity 
analysis will be undertaken to evaluate and compare impu-
tation results to complete case analyses. Multiple linear 
regression and logistic regression analyses will be used 
for the analyses, and data will be controlled for possible 
confounders, for example, baseline alcohol consump-
tion, social status, age etc in addition to the treatment.
Endpoints
The primary endpoint is per cent reduction in total 
number of heavy drinking days, defined as days with an 
excess intake of 60/48 g of alcohol per day (men and 
women, respectively) the previous 30 days from baseline 
to follow-up after 26 weeks of treatment, measured by 
TFLB method.
The secondary endpoints include changes in total 
alcohol consumption (g/30 days measured by TLFB), 
changes in number of days without alcohol consump-
tion and PACS score, change in AUDIT score, change in 
DUDIT score, change in cognitive performance on the 
SCIP-test, change in the liver parameters gamma-glutam-
yltransferase, alanine aminotransferase and PEth. Other 
parameters will be mean cell volume (MCV), changes 
in body weight, blood pressure, pulse, overall glycaemic 
control parameters (HbA1c), kidney function (p-creat-
inine, eGFR and urine albumin/creatinine ratio) and 
measures of health (SF-36 and SCL-92).
In addition to these clinical outcome parameters, we will 
explore the possible neuromolecular effects by measuring 
striatal DAT availability before and after administration 
of exenatide by use of SPECT. The possible neuroana-
tomical underpinnings of exenatide will be investigated 
by use of fMRI. Both examinations will be performed in 
two subgroups of patients treated with either exenatide 
or placebo. To have comparable standard data in this 
fMRI alcohol-related paradigm, we will include 25 healthy 
participants with no record of alcohol dependence.
The Consolidated Standards of Reporting Trials guide-
lines will be followed when final study data are reported.
Ethical considerations
On  ClinicalTrials. gov, it can be identified by the ID 
NCT03232112. Please see online supplementary appendix 
A for further details. The protocol has version control and 
dates as identifiers. Any amendments have to be approved 
by the above-mentioned authorities before implementation.
dIsCussIon
Data from animal studies suggest that the inhibitory effects 
of the GLP-1RA exendin-4 reduce alcohol consumption 
in rodents and this effect is likely mediated by stimula-
tion of the DAT 26). So far no human studies have been 
performed and the present trial therefore serves to inves-
tigate the effects of the GLP-1RA exenatide on alcohol 
consumption in patients with alcohol dependence as well 
as the associated neurobiological mechanisms. This trial 
is the first RCT (Randomized Clinical Trial) to investigate 
the effects of GLP-1R stimulation on alcohol consump-
tion in patients diagnosed with alcohol dependence.
Limitations
The measurement of the primary endpoint of the study, 
that is, change in heavy drinking days, is self-reported 
and retrospective, and might therefore have limited reli-
ability. In the present study, we use the TLFB method 
which has been extensively tested and evaluated.32 Self-re-
ported measurements can be influenced by several factors 
including social factors characteristics in the respondent 
group.45 For example, it is known that patients with 
alcohol dependence tend to describe themselves more 
negatively, that is, having more heavy drinking days etc, 
than suggested by data from more objective sources, for 
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example, blood samples.32 However, when patients have 
alcohol in the blood, the opposite is seen, that is, an 
underestimation of the alcohol intake.32 Thus, to limit 
the possible bias from different factors, the TLFB will be 
filled out in close cooperation with the patient in a stan-
dardised setting. In addition, the patients will do a breath 
alcohol test prior to all examinations.
Another limitation of the study is that the treatment is 
not evaluated long term. We also considered adding a third 
arm comparing exenatide to one of the established add-on 
treatments (all pharmacological treatments is considered 
as an add-on to CBT). However, adding a third arm would 
have increased the complexity and cost of the trial consider-
ably. A weakness of the present study is the lack of blinded 
placebo pens making weekly injections of exenatide by the 
study nurse necessary, which increases the risk of selection 
bias, as the design requires a very compliant patient, that 
is, patients having less resources might not participate. 
Additionally, some patients might choose not to participate 
because of needle phobia.
strengths
A significant advantage of the present study is the exten-
sive use of unbiased, biological measurements, that is, 
biomarkers in blood and urine and brain scans. A system-
atic review of the biomarker PEth thus showed a signifi-
cant statistical difference when comparing heavy drinkers 
(ie, >60 g of alcohol per day) from persons consuming 
less,46 making it very useful in the present study as we will 
be able to assess the correlation between the self-reported 
alcohol intake and PEth. Another advantage is the use of 
the brain imagining techniques SPECT and fMRI. The 
brain scans will allow the investigation of the possible 
neuroanatomical underpinnings of the treatment. A defi-
nite strength of the study is the long treatment period, 
that is, 26 weeks, when comparing to similar studies with 
study durations of typically 8–12 weeks.47 48 This relatively 
long treatment period will allow a better understanding of 
the true effects of exenatide as it corresponds to a more 
realistic setting with an ongoing risk of relapse persisting 
way longer than just a few months.4 Also, the design, that is, 
double-blinded, randomised, placebo-controlled, is an 
advantage as it reduces experimental bias, ensures balance 
in the two treatment groups and gives a direct estimate of 
the possible effect of exenatide. In addition, the present 
injection set-up allows us to verify, that the injections have 
been administered to the patients.
Perspectives
If GLP-1R stimulation proves efficacious in the treatment 
of alcohol dependence, it can be implemented in future 
treatment relatively easy as exenatide is already used in the 
clinic and the injections are designed for self-distribution. 
Further, per oral GLP-1RAs may be on the market within a 
few years, which would possible increase compliance even 
more. In addition, assessment of the neuronal underpin-
nings of the potential treatment effects will increase insight 
into neurobiological targets for future treatments.
trial status
Patient enrolment started in August 2017 and is ongoing 
until 114 patients have been randomised and received first 
injection.
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